

ELMMB Formulary Update

July 2017

Subscribe Now

And be one of the first to know...

BLACK traffic Light - not recommended for prescribing in primary or secondary care.

- **Elfornithine cream** – facial hirsutism. Limited evidence of efficacy & improvement in quality of life.
- **Bevacizumab (Avastin®)** - EGFR mutation-positive non-small-cell lung cancer – **appraisal terminated** – [NICE TA436](#)
- **Tenofovir alafenamide** – Chronic hepatitis B – **appraisal terminated** – [NICE TA435](#)
- **Liothyronine** - Monotherapy or add on treatment in refractory hypothyroidism
- **Pegylated liposomal irinotecan** – (Onivyde) – Pancreatic cancer in adults not recommended in [NICE TA440](#)
- **Nortriptyline** – depression and neuropathic pain.
- **Elotuzumab (Empliciti™)** – Previously treated multiple myeloma – **appraisal terminated** – [NICE TA434](#)
- **Ibrutinib with bendamustine & rituximab** – relapsed or refractory chronic lymphocytic leukaemia after systemic therapy – **appraisal terminated** – [NICE TA437](#)
- **Pitolisant (Wakix®)** -Narcolepsy with or without cataplexy in adults
- **Botulinum Toxin (Botox®)** hyperhidrosis associated with social anxiety
- **Potassium hydroxide topical** - Molludab® - molluscum contagiosum.
- **Alectinib** – Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer – **appraisal terminated** – [NICE TA438](#)
- **Panitumumab (Vectibix®)** – in combination with chemotherapy for the treatment of metastatic colorectal cancer – **appraisal terminated** – [NICE TA240](#) updated
- **Afatinib** – locally advanced or metastatic squamous non-small-cell lung cancer – **appraisal terminated** – [NICE TA444](#)
- **Ferric maltol (Ferracru®)** - Iron deficiency anaemia in patients with Inflammatory Bowel Disease
- **Imipramine** – depression and neuropathic pain.
- **Trimipramine** – depression and neuropathic pain.

RED traffic light - Primary care prescribers should not be asked to prescribe (** denotes NHS England Commissioned)

- **Cetuximab and panitumumab** – previously untreated metastatic colorectal cancer – an option in [NICE TA439](#)
- **Daclizumab* (Zinbrya®)** – relapsing-remitting multiple sclerosis as an option in [NICE TA441](#)
- **Spiro lactone 250mg/5mL, 50mg/5mL, 5mg/5mL, 100mg/5mL** – potassium sparing diuretic
- **Ustekinumab** – Active psoriatic arthritis – an option in [NICE TA340](#) updated
- **Ixekizumab* (Taltz)** – moderate to severe plaque psoriasis an option in [NICE TA442](#)
- **Certolizumab pegol & Secukinumab** – active psoriatic arthritis after inadequate response to DMARDs as an option in [NICE TA445](#)
- **Temocillin (Negaban®)** -- an extra option in more resistant organisms.
- **Ustekinumab** – moderate to severe psoriasis in adults- an option in [NICE TA180](#) (updated March 2017)
- **Obeticholic acid (Ocaliva)** – primary biliary cholangitis an option in [NICE TA443](#)
- **Carbocisteine oral solution 250mg/5ml** – paediatric use only.
- **Chlorothiazide 250mg/5mL, 25mg/5mL** – diuresis.
- **Trazodone Liquid 50mg/5mL** – depression, anxiety.

AMBER Traffic Light - initiated by specialists but may then be passed to primary care for prescribing

- **Pilocarpine tablets (Salagen®)** – radiation-induced xerostomia & Sjogren's syndrome. Agreed as 2nd line management when 1st line topical agents have not been effective.
- **Glycopyrronium liquid (Colonis Pharma Glycopyrronium liquid 1mg/5mL)** – more cost effective, prescribe as brand. Tablets removed from formulary
- **Sodium bicarbonate oral solution** – prescribe as SodiBic 1mmol/1mL (Arjun)
- **Sodium Chloride Solution** – prescribe as SodiClor 5mmol/1mL Arjun



ELMMB Formulary Update July 2017.....

Subscribe Now

And be one of the first to know...

GREEN Traffic Light - may be prescribed by all prescribers within local or national recommendations

- **Buprenorphine Transdermal 96 hourly patches** - *Bupeaze[®]* preferred brand for new patients.
- **Salmeterol/fluticasone propionate (MDI & DPI)** - *AirFluSal[®]* preferred choice where *Fostair[®]* and *Duoresp[®]* are not suitable.
- **Fentanyl patches** - *Matrifen[®]* patches
- **Buprenorphine Transdermal weekly patches** - *Butec[®]*, *Sevodyne[®]* preferred brands for new patients (*Butrans[®]* removed from formulary).
- **Ethinylestradiol 30mcg/drospenone 3mg** - *Yiznell[®]*, *Lucette[®]*
- **Morphine SR oral** – MST tablets
- **Optilube Active Sterile Lubricating Jelly** – with anaesthetic and antiseptic
- **Quetiapine MR** – *Sondate[®] XL* added to formulary (*Ebesque XL* discontinued)
- **Ondansetron tablets** – all conditions, including hyperemesis (off licence use).

Guidelines

- [Combined diphtheria, tetanus acellular, pertussis & inactivated polio vaccine PGD \(dTaP/IPV\)](#)
- [Rheumatoid Arthritis Pathway - updated](#)
- [Prescribing Nutritional Supplements Post Bariatric Surgery](#)
- [Omeprazole MUPS PIL](#)
- [Psoriasis in Primary Care Guideline](#)
- [Empagliflozin \(*Jardiance[®]*\) – Position Statement](#)
- [Methotrexate Shared Care Guideline](#)
- [Prescribing Oral Nutrition Supplements for Care Home Residents – policy statement](#)
- [Food Fortification Resources](#)
- [Prescribing Oral Nutrition Supplements for Care Home Residents – Patient Information Leaflet](#)

Other

- [MHRA reclassifies Nasonex Allergy Control Nasal Spray – product soon to be available OTC](#)
- [MHRA reclassifies Otrivine Extra Dual Relief Nasal Spray – soon to be available Over-the-counter](#)
- [Medicines Management Board Minutes 2017](#)
- [Blood Glucose Meters Range – updated](#)
- [Catheter Associated Urinary Tract Infection Poster](#)
- [NICE Bites Bulletins 2017](#)
- [Prescribing Hot Topics](#)
- [Drug Safety Updates MHRA 2017 Maloff Protect – successfully reclassified – now available to buy over-the-counter](#)

'Follow' us on  or 'Like' us on 

Email interface@eastlancashireccg.nhs.uk with any comments or questions